Forte Biosciences, Inc. (FBRX) - Q1 2026 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended March 31, 2026. Forte Biosciences is a clinical-stage biopharmaceutical company focused on autoimmune diseases. Its lead product candidate, FB102, is an anti-CD122 monoclonal antibody currently in Phase 2 trials for celiac disease and Phase 1b trials for non-segmental vitiligo and alopecia areata. The company has no approved products and has not generated any revenue from product sales.
Key Financial Metrics
| Metric (in thousands) | Q1 2026 | Q1 2025 |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(22,136) | $(15,656) |
| Net Loss Per Share (Basic/Diluted) | $(1.24) | $(1.37) |
| Operating Expenses | $22,439 | $16,124 |
| Cash and Cash Equivalents (End of Period) | $58,223 | $45,856 |
| Net Cash Used in Operating Activities | $(18,808) | $(10,355) |
| Accumulated Deficit | $(245,509) | $(169,654) |
Material Changes vs. Prior Period
- Increased Operating Expenses: Total operating expenses rose by $6.3 million (39%) to $22.4 million. This was driven primarily by a $7.8 million increase in Research and Development (R&D) expenses, attributed to clinical costs for the Phase 2 celiac trial and Phase 1b trials for vitiligo and alopecia areata.
- Decreased G&A Expenses: General and Administrative expenses decreased by $1.5 million to $2.0 million. This reduction was largely due to a $2.3 million interim legal settlement payment received from Palms Insurance Company in the prior year, which is not recurring.
- Widened Net Loss: Net loss increased by $6.5 million to $22.1 million, reflecting the higher R&D spend.
- Cash Burn: Net cash used in operating activities increased by $8.5 million to $18.8 million.
Guidance, Outlook, and Risks
- Subsequent Financing: On April 8, 2026 (post-period), the company closed a public offering (the "2026 Offering") raising gross proceeds of $172.5 million (net proceeds of $162.1 million). Management believes existing cash plus these proceeds will fund operations for at least 12 months.
- Clinical Milestones: Topline data for the Phase 2 celiac study, Phase 1b vitiligo trial, and Phase 1b alopecia areata study are all expected in 2026.
- Legal Proceedings: The company secured a judgment in its lawsuit against its D&O insurance carriers (Wesco and Palms). Palms paid $2.3 million in March 2026, and Wesco paid $2.5 million in April 2026.
- Risks: The company faces significant risks regarding the sufficiency of capital to complete development, the uncertainty of clinical trial outcomes, and reliance on third-party manufacturers and CROs. There is no assurance of future profitability.
Investor Verification Checklist
- Verify the impact of the $172.5 million April 2026 financing on the company's runway and dilution profile.
- Monitor the topline data releases expected in 2026 for the Phase 2 celiac and Phase 1b vitiligo/alopecia trials.
- Review the status of the University of Massachusetts patent litigation (Post-Grant Review of Patent No. 11,278,505) which is currently on appeal.
- Assess the sustainability of R&D spending given the $18.8 million quarterly cash burn from operations.
- Confirm the company's compliance with Nasdaq listing requirements following the 2024 reverse stock split.